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Abstract 
Conflict resolution in genomic variant interpretation is a critical step towards 
improving patient care. Evaluating interpretation discrepancies in copy number 
variants (CNVs) typically involves assessing overlapping genomic content with focus on 
genes/regions that may be subject to dosage sensitivity (haploinsufficiency (HI) and/or 
triplosensitivity (TS)). CNVs containing dosage sensitive genes/regions are generally 
interpreted as “likely pathogenic” (LP) or “pathogenic” (P), and CNVs involving the same 
known dosage sensitive gene(s) should receive the same clinical interpretation. We 
compared the Clinical Genome Resource (ClinGen) Dosage Map, a publicly available 
resource documenting known HI and TS genes/regions, against germline, clinical CNV 
interpretations within the ClinVar database. We identified 251 CNVs overlapping known 
dosage sensitive genes/regions but not classified as LP or P; these were sent back to 
their original submitting laboratories for re-evaluation. Of 246 CNVs re-evaluated, an 
updated clinical classification was warranted in 157 cases (63.8%); no change was 
made to the current classification in 79 cases (32.1%); and 10 cases (4.1%) resulted in 
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other types of updates to ClinVar records. This effort will add curated interpretation 
data into the public domain and allow laboratories to focus attention on more complex 
discrepancies. 
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Introduction 
Advances in genetic testing technologies have allowed the genomics community to 
greatly expand its ability to diagnose and care for patients. Historically, genetic 
diagnoses have been made using a “phenotype-first” approach, where a patient’s clinical 
features were used to determine a possible clinical diagnosis, and genetic testing was 
ordered (if available) to confirm.  Today, many diagnoses are “genotype-first,” where 
genome-wide assays, such as chromosomal microarray (CMA), whole exome sequencing 
(WES), or whole genome sequencing (WGS) are ordered as an initial diagnostic step 
(Mefford, 2009; Stessman, Bernier, & Eichler, 2014).  Variants identified as a result of 
this testing often lead the clinician to a specific diagnosis, one that may not have been 
readily apparent given the presenting clinical features, particularly if those features are 
nonspecific, such as developmental delay.  In this “genotype-first” era, the clinical 
interpretation of genomic test results is of paramount importance, as these results may 
lead a clinician to confirm or refute a particular diagnosis, and may ultimately have an 
effect on a given patient’s medical management.  Ensuring that laboratories provide 
accurate and consistent variant interpretations is a critical step toward improving 
patient care. 
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The increasing clinical usage of genome-wide assays required laboratories to be 
prepared to interpret variants that may occur throughout the genome.  Interpreting 
variants in genes or genomic regions with which a laboratory has little to no experience, 
or about which little is known, is challenging.  As clinical genomic testing became more 
routine, the genomics community recognized that making variant interpretations and 
the evidence supporting them publicly available could potentially help with these 
limitations.  One early example of a community effort to encourage genomic data 
sharing was the International Standards for Cytogenomic Arrays (ISCA) Consortium, a 
group focused on building standards and encouraging collaboration amongst those 
laboratories performing clinical CMA testing (Miller et al., 2010).  The ISCA Consortium 
was among the first groups to make data obtained from clinical testing publicly 
available through the National Center for Biotechnology Information’s (NCBI) dbVar 
database (Kaminsky et al., 2011). This and other shared datasets became essential tools 
for the clinical interpretation of copy number variants (CNVs) (Coe et al., 2014; Cooper 
et al., 2011; MacDonald, Ziman, Yuen, Feuk, & Scherer, 2014). As the utility of sharing 
genomic variants with clinical interpretations became more apparent, NCBI established 
ClinVar, a publicly available repository of genomic variation and its relationship to 
human health (Landrum et al., 2014).   
 
As more clinical laboratories began to make their variant interpretation data publicly 
available through ClinVar, variant interpretation discrepancies became more apparent 
(Lincoln et al., 2017; Yang et al., 2017).  Interpretation discrepancies can arise for a 
number of reasons, including (but not limited to): time (new evidence may have 
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emerged since a laboratory last evaluated the variant); access to information (one 
laboratory may have access to information that another may not, such as extensive 
internal databases, segregation or phenotype information for a particular patient, etc.); 
opinion (though evaluation guidelines have been published for both sequence (Richards 
et al., 2015) and copy number variants (Kearney et al., 2011), there is still a level of 
subjectivity involved when assessing the strength of particular pieces of evidence); and 
human error (data entry errors, etc.). The transparency provided by ClinVar, however, 
has encouraged many laboratories to work together to identify the reasons behind 
these discrepancies and resolve them, a powerful step toward more standardized 
variant interpretations and ensuring quality within and across laboratories (Garber et 
al., 2016; Harrison et al., 2017).  
 
Thus far, the majority of reported conflict resolution efforts involving ClinVar data have 
focused on sequence-level variants, while limited review and re-analysis has been 
performed for CNV data. The major challenge to identifying and resolving potential CNV 
interpretation discrepancies has to do with their inherent singular nature. With the 
exception of recurrent events (such as those mediated by segmental duplications), most 
CNVs have unique breakpoints. In many cases, other CNVs with matching breakpoints 
are not available for direct comparison.  Even determining when a conflict exists 
between two or more CNVs is difficult; though they may have areas of overlap, 
important genomic features may exist within the non-overlapping regions, providing 
logical reasons for differing classifications.  For example, even though two deletions 
may overlap the same known haploinsufficient gene, one may be interpreted as 
“pathogenic” due to the fact that it involves most of the gene, while the other may be 
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interpreted as “variant of uncertain significance” or “likely benign” because it overlaps 
only a non-coding exon, or only exon(s) involved in an isoform not thought to be 
clinically relevant, etc. Potential CNV conflicts must be evaluated on the basis of 
overlapping genomic content, with special focus on those genes or genomic regions that 
may be subject to dosage sensitivity - haploinsufficiency (HI) and/or triplosensitivity 
(TS). 
 
To facilitate the process of genomic content evaluation and promote interpretation 
consistency, the ISCA Consortium began systematically evaluating genes and genomic 
regions for dosage sensitivity in 2011 (Riggs et al., 2012).  Though the ISCA Consortium 
has officially become part of the Clinical Genome Resource (ClinGen), a National 
Institutes of Health (NIH)-funded effort dedicated to identifying clinically relevant genes 
and variants for use in precision medicine and research (Rehm et al., 2015), these 
activities remain ongoing.  Dosage evaluations are made publicly available through the 
ClinGen Dosage Sensitivity Map website 
(https://www.ncbi.nlm.nih.gov/projects/dbvar/clingen/).   For each individual gene or 
genomic region, current medical literature is evaluated for evidence supporting or 
refuting dosage sensitivity as the mechanism for any associated constitutional disease.  
Evidence for HI and TS is considered separately, and for each gene and genomic region, 
both a haploinsufficiency and triplosensitivity score are provided, corresponding to the 
strength of the available evidence for each.  Genes/regions receiving the highest score 
(3) are considered to have “sufficient” evidence supporting HI and/or TS as a 
mechanism of disease.  In general, CNVs containing genes or genomic regions with an HI 
or TS score of 3 should be classified as pathogenic (P) or likely pathogenic (LP), unless 
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there is evidence to suggest otherwise (Riggs et al., 2012).  For example, a deletion fully 
encompassing a known HI gene should be interpreted as P/LP, whereas a deletion fully 
contained within an intron (and unlikely to result in loss of function) of a known HI 
gene may not.  Likewise, a one copy gain that fully contains a known TS gene (whole 
gene duplication) should be classified as P/LP, whereas a partial gene duplication that 
contains one or both breakpoints within a gene, and could in fact disrupt gene 
expression, may not, unless the disrupted gene is also a known HI gene.  Other factors to 
consider when evaluating the clinical significance of a copy number gain include the 
location and orientation of the additional genomic material. 
 
As of late 2017, ClinVar contained over 19,000 CNVs; approximately 17% of these 
(3164) were deposited as the result of the initial efforts of the ISCA Consortium, and 
have not been updated since they were initially made publicly available in 2011 
(Kaminsky et al., 2011).  In an effort to increase the quality of CNV interpretations 
available to the genomics community through ClinVar, we used evidence scores from 
the ClinGen Dosage Sensitivity Map to identify CNVs with interpretations that appear to 
be in conflict with current understanding of the genes and/or genomic regions they 
overlap. As evidence supporting dosage sensitivity of genes or genomic regions included 
within a particular CNV may have emerged since these CNVs were last evaluated, the 
original submitting laboratories were contacted to re-evaluate these CNVs with 
currently available evidence.  This effort represents an important first step in 
establishing a CNV conflict resolution process that may be utilized beyond resolution of 
conflicts in ClinVar.  In addition, this work paves the way for the identification and re-
evaluation of other CNV classification conflict types, including inter- and intra-
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laboratory CNV conflicts, conflicts with other evidence-based scoring and/or predictive 
dosage sensitive metrics, and conflicts with sources of CNV data in the general 
population (such as the Database of Genomic Variants).  
 
Methods 
The ClinGen Dosage Sensitivity Map 
As of August 2017, the ClinGen Dosage Sensitivity Map included dosage sensitivity 
evaluation on 1303 single genes and genomic regions (both recurrent, such as the 
16p11.2 region associated with neurodevelopmental disorders [MIM:611913, 614671] 
and non-recurrent, such as the 4p13.6 region associated with Wolf-Hirschhorn 
syndrome [MIM:194190]).  At that time, there were 257 genes and 38 genomic regions 
reaching the threshold of “known” dosage sensitive (HI and/or TS score of 3) (see Supp. 
Table S1 for a full list).  This list of 295 known dosage sensitive genes/regions was 
downloaded from the ClinGen Dosage Sensitivity Map website 
(ftp://ftp.ncbi.nlm.nih.gov/pub/dbVar/clingen) and used to compare against CNVs in 
ClinVar.    
 
Identification of Potential Conflicts in ClinVar 
Variant and clinical significance data were imported into a local database (Neo4j, 
Malmo, Sweden) from NCBI’s ClinVar database (XML full release, Aug. 2017). From the 
ClinVar XML, we selected variants with type “copy_number_gain” or 
“copy_number_loss.” Variants that were not mapped to GRCh38 were mapped using the 
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NCBI remap tool. The GRCh38 coordinates of each CNV were then compared for overlap 
with all exons of genes in the dosage map using an algorithm written in the Clojure 
language. Detected overlaps of exons and variants were stored back in the Neo4j 
database. This database was then queried for potential conflicts of interpretation; 
deletions overlapping a HI gene and interpreted as benign (B), likely benign (LB), or 
variant of uncertain significance (VUS) were identified as potential conflicts (Figure 1A).  
As intragenic duplications could potentially result in loss of function, only duplications 
completely encompassing a TS gene and interpreted as B, LB, or VUS were considered 
potential conflicts.  
 
A different process was used to detect potential conflicts with dosage sensitive genomic 
regions annotated in the dosage map.  Several of our dosage sensitive genomic regions 
are non-recurrent; to annotate these within the dosage map, coordinates are manually 
selected by the ClinGen Dosage Sensitivity working group, typically based on the 
established critical region or smallest genomic range reported in the literature to be 
associated with the clinical phenotype.  A description of how the coordinates were 
determined is included in each region entry (for example,  see 
https://www.ncbi.nlm.nih.gov/projects/dbvar/clingen/clingen_region.cgi?id=ISCA-
37434).  Historically, these manually curated coordinates have been recorded using 
build GRCh37; updating these coordinates to GRCh38 will require manual review to 
ensure intended genes/regions are included, a process currently underway within the 
ClinGen Dosage Sensitivity working group.  Since GRCh38 coordinates were not 
available for all dosage sensitive genomic regions in August 2017, potential conflicts 
were manually identified using the UCSC Genome Browser.  The browser was 
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configured to show only variants in the publicly available “ClinGen CNVs” track with 
“benign”, “likely benign”, or “uncertain” clinical significance interpretations.  Each 
nstd45 region was then viewed in the genome browser on the GRCh37 build, and all 
variants that overlapped with at least 50% of a given region and had a 
type/interpretation that conflicted with the region were recorded.  For instance, if a 
variant was a “benign” copy number loss covering at least 50% of a haploinsufficient 
region, it would be recorded as a conflict. 
 
In total, we initially identified 284 potential conflicts (Figure 2).  Eighteen CNVs that 
were identified as part of research testing and/or from somatic tissue were excluded.  
An additional 15 CNVs appeared to have problems with remapping to GRCh38 (for 
example, a dosage sensitive gene was contained within the remapped coordinates but 
not the original submitted coordinates, or vice versa).  These CNVS were also excluded 
from further analysis. 
 
Conflict Resolution 
Between August-September 2017 and January-February 2018, two rounds of CNV 
conflict resolution activities were performed. A total of 251 potential conflicts were sent 
to 14 different original submitting laboratories for re-evaluation (see Supplemental 
Information for the full list).  For each CNV, the submitting laboratory received a 
summary of the originally submitted information (variant coordinates; original 
submitted interpretation; associated sex, phenotype, inheritance information, if 
available; ClinVar and dbVar identifiers).  The specific dosage sensitive gene/genomic 
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region that triggered each conflict was also provided.  Laboratories were asked to re-
evaluate and, if warranted, re-classify the CNV in light of currently available evidence.  
Participating laboratories were asked to return a new classification (if applicable) and a 
free-text rationale for their decision.  The free text rationales were reviewed and 
grouped into general categories for analysis. 
 
Results 
Twelve of 14 laboratories re-evaluated 246 of the 251 potential conflicts, for a response 
rate of 98%; two laboratories representing 5 potential conflicts did not respond to 
requests for participation (a complete list of all re-evaluated cases is available in the 
supplemental material). Of the 246 re-evaluated CNVs, 125 (50.8%) overlapped a 
known dosage sensitive gene (121 deletions overlapping HI genes and 4 duplications 
fully encompassing TS genes), and 121 (49.2%) represented CNVs overlapping a known 
dosage sensitive region (34 deletions overlapping HI regions, 87 duplications 
overlapping TS regions).  As suspected, many of these cases had not been evaluated in 
several years; 74.3% (183) of the cases had last been evaluated five or more years ago 
(see Supp. Table S2 for all original dates of evaluation).  In all, 155 (63.0%) of the re-
evaluated potential conflicts resulted in updated classifications; 81 (32.9%) resulted in 
no change to the original classification; and 10 (4.1%) resulted in some “other” type of 
update to the ClinVar record, discussed in further detail below (Figure 3).  Of the 236 
cases where a re-classification decision (yes or no) was made, 78.4% (n=185) were 
returned with a free-text description of the rationale supporting their decision, whereas 
21.6% (n=51) of the CNVs were returned without a corresponding decision rationale. 
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Updated Classifications 
After re-evaluation by the original submitting laboratory, 63.0% (n=155) of the 
potential conflicts resulted in updated classifications.  Potential conflicts involving 
dosage sensitive genomic regions received updated classifications more frequently than 
those involving dosage sensitive genes (86.0% (104/121) vs. 40.8% (51/125), 
respectively). Perhaps not surprisingly (based on the selection criteria), most potential 
conflicts that did result in updated classifications were updated to P/LP (94.8%, n=147) 
(Figure 4). Most of the updated P/LP CNVs were originally classified as VUS (89.0%), 
likely reflecting emergence of new data.    
 
Approximately 5.2% of re-evaluated CNVs receiving updated classifications (n=8) were 
not upgraded to P/LP: 2 cases were upgraded by one classification “step,” from B to LB 
(1.3%), while 6 cases were downgraded from VUS to LB (3.9%).  All of these CNVs were 
deletions involving the same gene, NRXN1; haploinsufficiency of this gene has been 
associated with developmental brain disorders such as autism, intellectual disability, 
and schizophrenia (Autism Genome Project Consortium et al., 2007; Bucan et al., 2009; 
Ching et al., 2010; Gauthier et al., 2011; Lowther et al., 2017; Walsh et al., 2008). 
Investigation into their genomic content revealed that none of these deletions involved 
coding sequence, and were last evaluated between 2010-2012.  At this time, there have 
been several NRXN1 intronic deletion variants observed in normal populations 
cataloged in the Database of Genomic Variants (DGV) Gold Standard Dataset (Zarrei, 
MacDonald, Merico, & Scherer, 2015), though most are observed at less than the 1% 
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frequency threshold typically used to describe a variant as a polymorphism.  This 
information supports the re-classification of these variants to LB.  
 
In total, 9 potential conflicts (5.7%) underwent greater than two-step re-classification, 
changing from either B or LB to P or LP. In two of these cases (a deletion involving the 
PMS2 gene associated with Lynch syndrome [MIM:614337] and a 16p11.2 deletion 
[MIM:611913]), the laboratories indicated that changing knowledge over time played a 
role in their updated interpretation. In the other 7 cases, the laboratory indicated that 
the original submitted classifications were in error, though it was unclear where the 
error occurred (during the laboratory reporting process, during the data submission 
process, etc.).  
 
The remaining 138 (89.0%) cases with updated classifications changed from VUS to LP 
or P.  While most who provided a rationale (n=106) cited updated information 
emerging over time as the reason for the change (86.7%, n=92)), there were 8 cases 
from this group that also specifically noted an error in submission (the submitted 
interpretation was not the reported interpretation) as the reason for the change. From 
the data obtained as part of this study, it is unclear where the error occurred. 
 
The genomic region that generated the most potential conflicts with overlapping CNVs 
was the proximal, recurrent 16p11.2 region (MIM:614337, 614671).  Deletions and 
duplications of this region are now known to be involved in neurocognitive phenotypes, 
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such as autism, and known to exhibit variable expressivity and reduced penetrance 
(Bernier et al., 2017; D'Angelo et al., 2016; Fernandez et al., 2010; Kumar et al., 2008; 
Steinman et al., 2016; Weiss et al., 2008).  The clinical significance of this region was 
typically interpreted as uncertain when laboratories first started performing clinical 
microarray testing.  Variants at this region, particularly the duplications, were 
frequently observed in reportedly normal parents (who may not have had detailed, 
neurocognitive phenotyping), contributing to the misconception that they were not 
clinically relevant.  The clinical effects of this region are now better understood and, as 
such, the region has been evaluated as a known haploinsufficient and triplosensitive 
region according to the ClinGen Dosage Sensitivity Map.  Fifty-one cases were identified 
as being in potential conflict with this region (3 deletions, 48 duplications); most of 
these were originally interpreted as VUS (n=49), though one case each was interpreted 
as LB or B.  After re-evaluation, 50 of these cases were reclassified to LP/P; in one case, 
the submitting laboratory opted to keep the interpretation as VUS because the variant 
was observed in a mosaic state. 
 
No Change to the Original Classification 
Of the 246 cases that were re-evaluated, 32.9% (n=81) resulted in no change to the 
original interpretation. This decision was made more frequently for cases flagged as 
potential conflicts due to overlap with a dosage sensitive gene (51.2%, 64/125 potential 
gene conflicts) than for those flagged due to overlap with a dosage sensitive genomic 
region (14.0%, 17/121 potential region conflicts). Of those cases opting not to change 
their classification that provided a rationale for their decision (n=64), the most 
commonly cited reason for not changing the interpretation was because the case 
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involved a dosage sensitive gene on the X chromosome, and the patient was a female 
(43.8%, n=28).  These cases (female carriers of variants that most likely would have 
been interpreted pathogenic in males) were instead interpreted as either LB or VUS.    
 
Other reasons for deciding not to change the original classification involved the genomic 
context of the particular variant.  Among cases overlapping dosage sensitive genes, 
there were cases where the variant was completely intronic (n=6), involved only non-
coding exons (n=6), or involved only the last exon (and not expected to result in 
nonsense-mediated decay) (n=1).  There were three cases involving deletions of NRXN1 
where the laboratory noted that these three cases were observed several years ago on a 
lower-resolution array platform; they could not be certain whether the variants actually 
overlapped with any coding sequence of NRXN1, so they opted to keep the classification 
as VUS.  Among those cases overlapping dosage sensitive regions, the laboratory opted 
not to change the interpretation because the variants were smaller than the regions as 
defined by the ClinGen Dosage Sensitivity map (n=4).  These 4 cases involved two 
genomic regions that are not recurrent, segmental-duplication regions, are known to 
vary in size, and do not have a well-established critical region or causative gene 
(deletions of 4p16.3, associated with Wolf-Hirschhorn syndrome [MIM:194190], and 
deletions of 2q37.3, associated with a brachydactyly-intellectual disability phenotype 
[MIM:600430]). 
 
In several cases, the laboratory opted not to change their original classification because 
they did not agree with the ClinGen Dosage Sensitivity designations (i.e., they did not 
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feel that there was strong enough evidence to support the dosage sensitivity scores for 
these genes/regions) (n=9).  These 9 cases came from a single laboratory, and involved 
duplications of the 17q11.2 region (including NF1) (n=2); and duplications of the distal 
22q11.2 region (LCR22-D to LCR22-E or -F) (n=7).  Each of these duplications have been 
reported in association with varying neurodevelopmental phenotypes and reduced 
penetrance/variable expressivity.  The clinical significance of these types of events has 
historically been difficult to determine, given their nonspecific phenotype and presence 
in reportedly “normal” parents.  However, recent literature has shown that, when 
carefully phenotyped, “normal” carriers of certain CNVs do show subtle 
neurodevelopmental deficits (Kendall et al., 2017; Mannik et al., 2015; Stefansson et al., 
2014).   Given the laboratory’s concerns over the evidence supporting triplosensitivity 
of the 17q11.2 region (including NF1) and the distal 22q11.2 region (LCR22-D to 
LCR22-E), these regions will be re-evaluated by the ClinGen Dosage Sensitivity working 
group.   
 
Other types of updates 
Ten re-evaluations resulted in “other” types of updates to the existing ClinVar record.  
All 10 cases were flagged as potential conflicts due to overlap with a known dosage 
sensitive gene; there were no cases overlapping genomic regions in this category.  Upon 
re-evaluation, six cases were identified by the submitting laboratories as either artifacts 
of testing or false positive calls on array.  These cases were originally submitted as part 
of the original ISCA Consortium pilot data set (Kaminsky et al., 2011), and were 
observed when the laboratories first started performing clinical CMA testing.  After 
several additional years of experience, the laboratories are now easily able to identify 
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issues such as false positive calls due to poorly performing probes on certain array 
platforms. These 6 CNVs will be removed from ClinVar. 
 
Three additional CNVs came from a single laboratory that uses a third-party system to 
submit their data to ClinVar; in these three cases, this third-party process resulted in the 
inadvertent submission of variants that were identified but not originally classified or 
reported with “VUS” interpretations in ClinVar.  These CNVs will also be removed from 
ClinVar.  The tenth case was flagged as a potential conflict because it appeared to be a 
deletion involving the EHMT1 gene; haploinsufficiency of this gene has been associated 
with Kleefstra syndrome (MIM:610253).  Upon re-evaluation, the submitting laboratory 
noted that the observed case was actually a duplication; the case was mistakenly 
submitted to ClinVar as a deletion.  The copy number on this particular case will be 
corrected in ClinVar, and the original interpretation (VUS) will remain the same. 
 
Inconsistencies in interpretation of CNVs on the X chromosome 
As a result of the re-evaluation process, we identified an area of inconsistency among 
laboratories when interpreting CNVs involving the X chromosome.  Of all 246 re-
evaluated CNVs, 48 were flagged as potential conflicts due to overlap with dosage 
sensitive gene on the X chromosome. Of these, 41 had copy numbers of 1 or 3, implying 
that they were observed in females (sex of the tested individual is not consistently 
available in ClinVar records).  In 10 out of these 41 potential conflicts involving X-linked 
genes in females (24.4%), the laboratories did opt to change their classification from the 
original VUS to LP/P.  In the remaining 31 cases (68.9%), the laboratories did not opt to 
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change their classifications from their original VUS (n=16), LB (n=14), or B (n=1).  
Historically, CNV interpretation has been done in the context of the presenting 
individual - if the observed CNV was not believed to be related to the reason for testing, 
it may not have been interpreted as pathogenic.  For example, CNVs on the X 
chromosome in females, typically representing a carrier state, may receive 
classifications other than LP or P, to reflect the fact that these findings are likely not the 
cause of the individual’s reason for testing.  More recently, there has been a movement 
towards ensuring that variant pathogenicity is assessed independently of the presenting 
patient’s reason for referral, and that a variant should receive the same interpretation 
(on the basis of supporting evidence), regardless of the clinical context in which it is 
observed (Richards et al., 2015). For example, CNVs involving known dosage sensitive 
genes on the X chromosome should be interpreted as LP/P, regardless of whether they 
are observed in a male or a female; caveats regarding the clinical significance of this 
finding for the tested individual should be explained in the body of the report. Our work 
shows that laboratories are currently utilizing both approaches, resulting in 
inconsistency in the way X-chromosome CNVs are being classified for males and 
females.  Note that scenarios where the clinical significance for an individual patient 
may differ based upon their sex are not limited to variants on the X-chromosome; this 
issue may also arise with autosomal variants involving imprinted genes/regions, or sex-
limited phenotypes determined by autosomal loci. Updated CNV interpretation 
guidelines recommending that variant interpretation be uncoupled from clinical 
significance for a given individual should make these interpretations more consistent in 
the future. 
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Discussion 
Publicly available databases containing genomic variants and their clinical 
interpretations (such as ClinVar) represent an incredible resource for clinical 
laboratories, clinicians, and researchers; knowing that another group has observed a 
given variant, how they interpreted it, and the evidence they used to arrive at that 
conclusion can help shape one’s own evaluation of that variant.  In addition, by making 
their variant interpretations publicly available, laboratories are now more readily able 
to appreciate when their interpretations are in conflict with others.  This process has 
prompted collaborations between laboratories to resolve interpretation discrepancies, 
mainly among sequence-level variants (Garber et al., 2016; Harrison et al., 2017). 
 
Interpretation discrepancies among CNVs have been appreciated for some time 
(Tsuchiya et al., 2009), however, to our knowledge, this study represents the first 
organized, multi-laboratory effort to resolve them.  A conflict for a sequence variant is 
identified when different clinical interpretations exist for the same exact variant; 
resolving them involves reviewing currently available evidence for that single, well-
defined variant.  Because the majority of CNVs have unique breakpoints, our group has 
needed to take a different approach to discrepancy identification and resolution. Since 
there are often no other CNVs available with the exact same breakpoints for 
comparison, CNVs conflicts needed to be identified based on copy number, degree of 
overlap, and shared genomic content.  For this initial effort, we wanted to identify those 
CNVs most likely to warrant an interpretation update, and therefore focused on those 
CNVs that overlapped by at least 50% with a known dosage sensitive gene or genomic 
region, as defined by the ClinGen Dosage Sensitivity Map.  Indeed, 63.0% of those cases 
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sent for re-evaluation ultimately received updated interpretations, and 94.8% of those 
with updated classifications represented changes that were medically relevant (i.e., 
changes from B, LB, or VUS to LP/P).   These data suggest that this approach did 
effectively identify cases that were not aligned with current understanding of the genes 
or genomic regions involved.   
 
Since this was a pilot effort, we chose to use the evidence-based ClinGen Dosage 
Sensitivity Map as our standard for “known” dosage sensitive genes and genomic 
regions; these genes and genomic regions are designated as dosage sensitive after 
careful review and consideration of literature-based evidence that loss or gain of these 
genes/regions causes human disease.  Other methods have been developed to predict 
which genes may be haploinsufficient based on biologically relevant evidence 
(expression patterns, number of observed vs. expected loss of function (LOF) variants in 
the general population, etc.) and objective, statistical analysis (Huang, Lee, Marcotte, & 
Hurles, 2010; Lek et al., 2016; Petrovski, Wang, Heinzen, Allen, & Goldstein, 2013; Uddin 
et al., 2014; Uddin et al., 2016).  As the results of these metrics are computationally 
derived, they are able to annotate many more genes as potentially haploinsufficient 
than the manual ClinGen Dosage Sensitivity evaluation process, which can be extremely 
beneficial for hypothesis exploration in the research setting.  However, computational 
predictors also have limitations, and one must be aware of these when considering 
incorporating them into clinical use.  For example, metrics that account for differences 
between observed vs. expected loss of function variation data in the general population 
may not predict haploinsufficiency for genes in which LOF variants are known to cause 
adult-onset disorders that do not affect reproductive fitness, such as BRCA1.  We believe 
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there is a role for both types of methods (manual vs. computational) to evaluate dosage 
sensitivity; predictors could be used to triage the genes that the ClinGen Dosage 
Sensitivity team evaluates in the future.   Additionally, the 50% overlap threshold was 
chosen as a conservative measure to ensure that flagged cases had a sufficient degree of 
overlap with the dosage sensitive gene/region to justify asking the laboratory to re-
evaluate.  It could be argued that any degree of overlap with a known dosage sensitive 
gene/region should trigger a potential conflict reevaluation, however, efforts were 
made to strike a balance between identifying all possible conflicts and overloading 
participating laboratories with reevaluations unlikely to result in change.  Future 
studies will focus on identifying the ideal overlap threshold for these conflict resolution 
exercises.   
 
Due to the unique nature of most of the CNVs involved, instead of working with each 
other (a model frequently used by sequence variant conflict resolution groups), each 
laboratory was asked to re-evaluate their cases on their own, using currently available 
information. By leveraging the existing Dosage Sensitivity Map resource for the 
evaluation of genomic content, we were able to present participating laboratories with a 
summary of relevant information in an attempt to streamline their re-evaluation 
process.  The study is limited by the fact that we did not explicitly ask participants how 
useful they felt this was, however we are encouraged by our high participation and 
completion rate - 12 of 14 laboratories approached opted to participate, and all 12 labs 
completed 100% of their assigned re-evaluations.  It is possible that having an identified 
reason for re-evaluation - the fact that a case overlaps a specific gene/genomic region - 
makes the process of CNV conflict resolution more straightforward and manageable. 
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Given the success of this initial effort, we intend to apply this model to other, potentially 
more complex CNV discrepancies (Figure 1B).  Genes involved in other CNV 
discrepancies that have not been previously evaluated for dosage sensitivity can be 
triaged for evaluation by ClinGen, and, pending the results of the evaluation, could 
contribute to the resolution of the conflict. 
 
The ultimate intent of this effort was to increase the quality of clinically interpreted 
CNVs available for community use in ClinVar, and we feel this was accomplished in 
several different ways.  The first was facilitating the update of interpretations that were 
not in line with current understanding of dosage sensitive genes and genomic regions; 
however, not all cases re-evaluated resulted in an updated clinical interpretation.  This 
was expected; even if a CNV overlaps a dosage sensitive gene/genomic region by 50%, it 
still may not overlap critical exons/regions.  However, the evaluation process as a 
whole, regardless of whether or not the interpretation was updated, provided valuable 
information that can be used to update the existing ClinVar record, another way in 
which the quality of these particular cases was increased.  For all cases re-evaluated 
(n=246), the “Date Last Evaluated” field will be updated.  Approximately 74.4% of these 
cases had not been evaluated in five years or more; once this information is updated in 
ClinVar, users can be confident that the interpretations have been recently reviewed by 
the laboratory and are current.  Additionally, now that processes for potential conflict 
identification and re-review are in place, these conflict resolution exercises will take 
place more frequently.  Many re-evaluations (n=185 or 75.2%) included a rationale for 
the laboratory’s decision to update the classification or not, and this information can 
also be added to the ClinVar record to make users aware of what considerations went in 
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to the laboratories’ interpretations.  The re-evaluation process can result in richer 
information being added to the ClinVar record, outside of any potential interpretation 
change.  
 
Finally, identifying and correcting errors in ClinVar CNV submissions increases data 
quality. We identified several cases (n=22, 8.9% of all cases evaluated) that represented 
errors - from cases that should not be represented in ClinVar at all (false positives, etc.) 
to cases that had some kind of incorrect attribute (copy number, clinical interpretation, 
etc.).  For many laboratories, the ClinVar submission process involves at least some 
degree of manual data manipulation - for example, combining data that may exist in a 
variant calling system with data that may exist in a completely separate laboratory 
information management system, getting data to match with ClinVar’s controlled 
vocabulary when it may be different from one’s own, making sure potentially 
identifiable information is removed, etc.  These processes may introduce errors into the 
submission.  The ClinVar staff perform some “logic” checks on data as they are received; 
for example, making sure the coordinates listed for a given CNV are not larger than the 
chromosome it is on, etc.  Additional checks, such as comparing data to the ClinGen 
Dosage Map prior to submission to ensure that cases that overlap with known dosage 
sensitive genes or genomic regions have been interpreted as the laboratory intended, 
may prevent some of these errors from making it into the database.   
 
The process of CNV interpretation conflict identification and resolution is perpetual; 
new information regarding the dosage effects of genes and genomic regions is always 
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being uncovered, and CNV interpretations will change accordingly.  Community 
curation efforts such as the ClinGen Dosage Sensitivity Map are also constantly updated 
to reflect this knowledge.   Future CNV conflict resolution efforts will continue to use the 
Dosage Sensitivity Map to identify and mediate conflicts by checking CNVs submitted to 
ClinVar for overlap with current known dosage sensitive genes and genomic regions, as 
well as by triaging those genes involved in other, inter-laboratory conflicts that have not 
been previously evaluated for dosage sensitivity (Figure 1B).  The Dosage Map can serve 
as a valuable resource to identify those CNVs that require re-evaluation to align with 
current knowledge and provide laboratories with up-to-date dosage sensitivity 
information during the reassessment process with the ultimate goal of improving 
patient care. 
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Figure Legends: 
 
Figure 1: Schematic Representation of the CNV Discrepancy Identification and 
Resolution Process.  In this generic region of the genome, there are at least two 
potential conflicts involving CNVs overlapping by ≥50% with different clinical 
interpretations.  A) Conflict 1 involves known haploinsufficient (HI) Gene 3.  This 
information can be used to mediate the conflict resolution process. Likely pathogenic 
(LP)/pathogenic (P) interpretations are expected for deletions fully encompassing this 
gene, such as Deletions 1 and 5.  Deletions 2, 3, and 6 also fully encompass this gene, but 
are interpreted as variants of uncertain significance (VUS). These cases would be 
flagged for reevaluation by the submitting laboratory.  B) Assuming Conflict 1 is 
resolved by the reevaluation process, Conflict 2 can be assessed.  To mediate this 
process, Genes 4, 5, and 6 would be triaged for dosage sensitivity evaluation.  The 
dosage evaluation process could resolve the conflict in and of itself; for example, if Gene 
4 were found to be a known HI gene, Deletions 4 and 7 would no longer be in conflict, as 
Deletion 7 does not include Gene 4. 
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Figure 2: Number of potential conflicts identified and sent for re-evaluation by 
original submitting laboratory. 
 
 
Figure 3: Percentage of cases re-evaluated by the original submitting laboratory 
(n=246) resulting in updates to the ClinVar record. 
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Figure 4: Classification Updates.  Laboratory re-evaluation resulted in updated 
classification in 155 cases; the exact classification changes are shown here.  Overall, 
94.8% of cases with updated classifications were changed to likely pathogenic (LP) or 
pathogenic (P). 
 
 
 
 
 
 
 
 
